STOCKHOLM, Feb. 11, 2022 /PRNewswire/ --
Fourth quarter
- Revenue amounted to €376.3m (€297.7m), an increase of 26.4%
with an organic growth of 21.6%.
- Operating profit (EBIT) was €41.6m (€29.9m), representing an
operating margin of 11.1% (10.1%).
- Net profit amounted to €28.4m (€18.8m), which represents a net
profit margin of 7.6% (6.3%).
- EBITDA was €75.1m (€53.1m), an increase by 41.6%. EBITDA margin
was 20.0% (17.8%).
- EBITDAaL amounted to €56.9m (€41.2m), corresponding to an
EBITDAaL margin of 15.1% (13.9%).
- Net cash flow from operating activities was €53.9m
(€39.0m).
- Basic/diluted earnings per share were €0.186 (€0.123).
Full year
- Revenue amounted to €1,377.4m (€997.8m), an increase of 38.0%
with an organic growth of 38.1%.
- Operating profit (EBIT) was €159.4m (€61.3m), representing an
operating margin of 11.6% (6.1%).
- Net profit amounted to €106.6m (€27.3m), which represents a net
profit margin of 7.7% (2.7%).
- EBITDA was €270.4m (€157.5m), an increase by 71.7%. EBITDA
margin was 19.6% (15.8%).
- EBITDAaL amounted to €210.8m (€108.5m), corresponding to an
EBITDAaL margin of 15.3% (10.9%).
- Net cash flow from operating activities was €216.7m
(€155.1m).
- Basic/diluted earnings per share were €0.686 (€0.182).
- The board of directors proposes a dividend for 2021 of
€0.12 (€0.07) per
share.
REVENUE AND EARNINGS
|
€ millions
(€m)
|
Q4
2021
|
Q4
2020
|
Growth
|
FY
2021
|
FY
2020
|
Growth
|
|
Revenue
|
376.3
|
297.7
|
26%
|
1,377.4
|
997.8
|
38%
|
|
Operating profit
(EBIT)
|
41.6
|
29.9
|
39%
|
159.4
|
61.3
|
160%
|
|
Operating profit
margin
|
11.1%
|
10.1%
|
|
11.6%
|
6.1%
|
|
|
Net profit
|
28.4
|
18.8
|
51%
|
106.6
|
27.3
|
290%
|
|
Net profit
margin
|
7.6%
|
6.3%
|
|
7.7%
|
2.7%
|
|
|
Basic/diluted
earnings per share, €
|
0.186
|
0.123
|
51%
|
0.686
|
0.182
|
277%
|
|
|
|
|
|
|
|
|
EBITDA
|
75.1
|
53.1
|
42%
|
270.4
|
157.5
|
72%
|
|
EBITDA
margin
|
20.0%
|
17.8%
|
|
19.6%
|
15.8%
|
|
|
EBITDAaL
|
56.9
|
41.2
|
38%
|
210.8
|
108.5
|
94%
|
|
EBITDAaL
margin
|
15.1%
|
13.9%
|
|
15.3%
|
10.9%
|
|
|
EBITA
|
45.9
|
32.7
|
41%
|
171.2
|
76.9
|
123%
|
|
EBITA
margin
|
12.2%
|
11.0%
|
|
12.4%
|
7.7%
|
|
Definition and reconciliation of alternative performance
measures are available at
www.medicover.com/financial-information.
This interim report has not been subject to review by the
Company's auditor.
This is information that Medicover AB is obliged to make public
pursuant to the EU Market Abuse Regulation and the Securities
Markets Act. The information was submitted for publication through
the agency of the contact person set out below at 7.45 (CET) on
11 February 2022. This year-end
report and other information about Medicover is available at
medicover.com.
For full report, see attached pdf.
Financial Calendar
Annual
report week
13
Interim report
January-March 27
April
Annual general
meeting 27
April
Interim report
April-June 22
July
Interim report
July-September 3
November
For further information, please contact:
Hanna Bjellquist, Head of
Investor Relations
Phone: +46 70 303 32 72
E-mail: hanna.bjellquist@medicover.com
Conference call: A conference call for analysts and
investors will be held today at 09.30 CET. To listen in please
register here. To ask questions please dial in and use code:
4597901
SE: +46 (0)8-566 184 67
DE: +49 (0) 305 200 2085
UK: +44 (0) 2071 928 338
US: +1 646 741 3167
Medicover is a leading international healthcare and
diagnostic services company and was founded in 1995. Medicover
operates a large number of ambulatory clinics, hospitals,
specialty-care facilities,laboratories and blood-drawing
points and the largest markets are Poland and Germany. In 2020, Medicover had revenue of
EUR 998 million and more than 32,000
employees. For more information, go to www.medicover.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medicover/r/year-end-report-january-december-2021,c3504433
The following files are available for download:
|
https://mb.cision.com/Main/15662/3504433/1533511.pdf
|
Year-end report
2021
|